109 related articles for article (PubMed ID: 28739143)
21. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
Velikyan I; Sundin A; Eriksson B; Lundqvist H; Sörensen J; Bergström M; Långström B
Nucl Med Biol; 2010 Apr; 37(3):265-75. PubMed ID: 20346866
[TBL] [Abstract][Full Text] [Related]
22. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
23. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
24. Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice.
Maaß C; Rivas JR; Attarwala AA; Hardiansyah D; Niedermoser S; Litau S; Wängler C; Wängler B; Glatting G
Nucl Med Biol; 2016 Apr; 43(4):243-6. PubMed ID: 27067044
[TBL] [Abstract][Full Text] [Related]
25. Dosimetric measurements of (68)Ga-high affinity DOTATATE: twins in spirit - part III.
Hartmann H; Freudenberg R; Oehme L; Zöphel K; Schottelius M; Wester HJ; Wunderlich G; Kotzerke J; Brogsitter C
Nuklearmedizin; 2014; 53(5):211-6. PubMed ID: 25029274
[TBL] [Abstract][Full Text] [Related]
26. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy.
Kletting P; Muller B; Erentok B; Schmaljohann J; Behrendt FF; Reske SN; Mottaghy FM; Glatting G
Med Phys; 2012 Sep; 39(9):5708-17. PubMed ID: 22957636
[TBL] [Abstract][Full Text] [Related]
27. (90)Y-PET/CT Imaging Quantification for Dosimetry in Peptide Receptor Radionuclide Therapy: Analysis and Corrections of the Impairing Factors.
Fabbri C; Bartolomei M; Mattone V; Casi M; De Lauro F; Bartolini N; Gentili G; Amadori S; Agostini M; Sarti G
Cancer Biother Radiopharm; 2015 Jun; 30(5):200-10. PubMed ID: 25860616
[TBL] [Abstract][Full Text] [Related]
28. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
29. A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of
Siebinga H; de Wit-van der Veen BJ; Beijnen JH; Stokkel MPM; Dorlo TPC; Huitema ADR; Hendrikx JJMA
EJNMMI Res; 2021 Aug; 11(1):73. PubMed ID: 34398356
[TBL] [Abstract][Full Text] [Related]
30. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors.
Sandström M; Velikyan I; Garske-Román U; Sörensen J; Eriksson B; Granberg D; Lundqvist H; Sundin A; Lubberink M
J Nucl Med; 2013 Oct; 54(10):1755-9. PubMed ID: 23929824
[TBL] [Abstract][Full Text] [Related]
31. A PBPK model for PRRT with [
Vasić V; Gustafsson J; Nowshahr EY; Stenvall A; Beer AJ; Gleisner KS; Glatting G
Phys Med; 2024 Mar; 119():103299. PubMed ID: 38367588
[TBL] [Abstract][Full Text] [Related]
32. Uncertainty propagation for SPECT/CT-based renal dosimetry in (177)Lu peptide receptor radionuclide therapy.
Gustafsson J; Brolin G; Cox M; Ljungberg M; Johansson L; Gleisner KS
Phys Med Biol; 2015 Nov; 60(21):8329-46. PubMed ID: 26458139
[TBL] [Abstract][Full Text] [Related]
33. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.
Pfeifer A; Knigge U; Mortensen J; Oturai P; Berthelsen AK; Loft A; Binderup T; Rasmussen P; Elema D; Klausen TL; Holm S; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2012 Aug; 53(8):1207-15. PubMed ID: 22782315
[TBL] [Abstract][Full Text] [Related]
34. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
35. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Haug AR; Auernhammer CJ; Wängler B; Schmidt GP; Uebleis C; Göke B; Cumming P; Bartenstein P; Tiling R; Hacker M
J Nucl Med; 2010 Sep; 51(9):1349-56. PubMed ID: 20720050
[TBL] [Abstract][Full Text] [Related]
36. Personalized
Del Prete M; Buteau FA; Beauregard JM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
[TBL] [Abstract][Full Text] [Related]
37. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.
Rolleman EJ; Valkema R; de Jong M; Kooij PP; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):9-15. PubMed ID: 12483404
[TBL] [Abstract][Full Text] [Related]
38. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
39. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
[TBL] [Abstract][Full Text] [Related]
40. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]